Robb, you began this thread with the Drug Channels link and questions on how Walgreens would address the Grassley investigation. That investigation focuses on how some indigent clients do not always get the lowest price from hospital referrals to local pharmacy networks. You presented this issue as some significant "ticking time bomb" for Walgreens. The rest of us seem to disagree with your assessment.
340B is a small fraction of the Rx market. It is a big total market so even a small share has some significance, I grant you. But the portion that Walgreens has is fractional, the portion that has administrative issues or problems is likely miniscule and applies to all providers in the space. Moreover, even your link points out that much of the language in the program is vague, confusing and leaves much open for interpretation.
This stuff is inconsequential to Walgreens S/P in my opinion.
News 
Market Data 
Discover 
